Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
Passage Bio, Inc. (Nasdaq: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations. The data showcased PBFT02's ability to elevate CSF progranulin to supraphysiologic levels at the lowest tested dose, Dose 1, up to six months post-treatment. The company also shared strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
The recent announcement by Passage Bio, Inc. regarding the initial safety and biomarker data from their upliFT-D clinical trial represents a significant development in the field of gene therapy for neurodegenerative diseases. The focus on PBFT02, an adeno-associated virus (AAV)-delivery gene therapy, targets frontotemporal dementia (FTD) with granulin (GRN) mutations, a condition currently lacking approved disease-modifying treatments. The reported increase in cerebrospinal fluid (CSF) progranulin to supraphysiologic levels and its sustained presence up to six months post-treatment is a promising indicator of the therapy's potential efficacy.
From a medical research perspective, the trial's use of an AAV1 viral vector to introduce a functional GRN gene is a notable strategy for addressing the genetic root of FTD-GRN. The absence of serious adverse events (SAEs) and the mild to moderate nature of all treatment emergent adverse events (AEs) suggest a favorable safety profile, particularly after protocol adjustments to the steroid regimen for immunosuppression were made following the experience of patient 1. However, the long-term implications of supraphysiologic CSF progranulin levels remain to be fully understood and extended follow-up will be critical to ensure that the benefits outweigh any potential risks associated with gene therapy.
Passage Bio's strategic shift to focus on the development of PBFT02 for a broader range of adult neurodegenerative diseases, while seeking partnerships for clinical-stage pediatric programs, signals a proactive approach to pipeline optimization. The company's targeting of additional indications like FTD-C9orf72, ALS and Alzheimer's disease could potentially expand the addressable market for PBFT02, pending successful clinical outcomes and regulatory feedback. Investors should note that the pursuit of such an expansive strategy often requires substantial capital and resources and the company's ability to secure partnerships will be critical to manage costs and risk.
While the interim data is positive, the market's response may be tempered by the recognition that further clinical validation is required. The announcement of anticipated milestones, including the initiation of dosing for Cohort 2 FTD-GRN patients and the reporting of extended follow-up data, provides a roadmap for investors to track the company's progress. As the clinical trial progresses, key factors for financial stakeholders will include the therapy's competitive positioning, the potential size of the patient population and the company's capacity to navigate regulatory hurdles.
In the context of the biotechnology sector, Passage Bio's focus on gene therapy for neurodegenerative diseases aligns with a growing trend toward precision medicine. The interim results of the upliFT-D clinical trial may influence the competitive landscape by positioning PBFT02 as a front-runner in the race to address the unmet need in FTD-GRN treatment. The specificity of targeting granulin mutations and the apparent avoidance of dorsal root ganglion (DRG) toxicity are key differentiators that could set PBFT02 apart from other therapies in development.
Industry stakeholders will observe how Passage Bio navigates the complex regulatory environment and manages the scalability of PBFT02 production. The company's strategic pivot to expand the therapy's application to other neurodegenerative diseases could create synergies in research and development, but also necessitates careful management to avoid overextension. The long-term success of PBFT02 will depend on continued positive clinical data, the establishment of strategic partnerships and the ability to effectively commercialize the therapy in a competitive market.
12/20/2023 - 07:00 AM
Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatment Elevated progranulin levels were sustained at up to six months post-treatment Dose 1 of PBFT02 was generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in multiple additional adult neurodegenerative diseases Pursuing potential partnership opportunities for clinical-stage pediatric lysosomal storage disease programs including GM1 gangliosidosis Management to host a webcast presentation to review interim FTD data today at 8:30 a.m. ET PHILADELPHIA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN ) mutations. FTD is a form of early onset dementia with no approved disease-modifying therapies. Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
"We are proud to announce initial clinical data from our upliFT-D clinical trial, which showcases the ability of PBFT02 to elevate CSF progranulin to supraphysiologic levels at the lowest tested dose, Dose 1, up to six months post-treatment. We believe these data, surpassing our expectations based on preclinical non-human primate models, validate the compelling potential of PBFT02 to address progranulin deficiency—a key driver of disease progression in individuals with FTD-GRN ,” said Mark Forman, M.D., Ph.D., chief medical officer at Passage Bio.
FTD is one of the more common causes of early-onset dementia. In approximately 5 to 10 percent of individuals with FTD–approximately 18,000 individuals in the United States and Europe—the disease occurs because of mutations in the GRN gene, causing a deficiency of progranulin (PGRN). PGRN is a complex and highly conserved protein thought to have multiple roles in cell biology, development and inflammation. Emerging evidence suggests that PGRN deficiency may contribute to lysosomal dysfunction.
The upliFT-D clinical trial evaluates PBFT02 as a single dose delivered via intra-cisterna magna (ICM) injection. PBFT02 uses an AAV1 viral vector to deliver a functional copy of the GRN gene encoding PGRN to a patient's cells.
Topline interim results from first three patients in the uplift-D clinical trial
Safety (patient follow-up up to six months)
Dose 1 of PBFT02 was generally well-tolerated in patients 2 and 3, who received an enhanced steroid regimen following protocol amendment. No serious adverse events (SAEs). All treatment emergent adverse events (AEs) were mild to moderate in severity. No evidence of clinically significant immune response, hepatotoxicity or safety related imaging abnormalities. Patient 1 received a low level of immunosuppression (60 mg oral prednisone for 60 days) and experienced two SAEs that were both asymptomatic and consistent with an immune response. Following patient 1, the protocol was amended to increase the steroid regimen (1,000 mg IV methylprednisolone on days 1-3 followed by 60 mg oral prednisone through day 60) for patients 2 and 3. No evidence of dorsal root ganglion (DRG) toxicity, as measured by nerve conduction studies, and no complications were observed related to ICM administration across any of the three patients. Biomarkers
Dose 1 of PBFT02 treatment resulted in a 3.6 to 6.6-fold increase in CSF PGRN at day 30 (n=3) relative to baseline. CSF PGRN increased to supraphysiologic levels of 10.7 to 17.3 ng/mL at day 30, exceeding the range found in healthy adult controls of 3.3 to 8.2 ng/mL (n=61). CSF PGRN remained at supraphysiologic levels at six months with a concentration of 27.3 ng/mL (n=1). Plasma PGRN levels remained below levels found in healthy adult controls through the available follow-up period across all patients. "Driven by promising initial data for PBFT02 in FTD-GRN and evidence supporting progranulin’s role in neurodegeneration, we are refining our strategic priorities to explore the therapeutic potential of PBFT02 in multiple diseases, including FTD-C9orf72 , amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease,” said William Chou, M.D., president and chief executive officer at Passage Bio. “As we pursue this strategy, we are actively exploring potential partnerships to advance our GM1 gangliosidosis program as well as our other clinical-stage pediatric programs. This shift in strategy aims to optimize focus and resources and provides each of our gene therapy candidates the best chance to get to patients in need.”
Strategic Priorities
We are focused on the following key strategic priorities:
Continuing clinical development of PBFT02 to treat FTD-GRN . Pursuing PBFT02 in additional adult neurodegenerative diseases, including FTD-C9orf72 , ALS and Alzheimer’s disease. Prioritizing Huntington’s disease preclinical program through existing Penn Gene Therapy Program partnership. Pursuing potential partnership opportunities for clinical-stage pediatric programs in GM1 gangliosidosis, Krabbe disease and metachromatic leukodystrophy (MLD). Anticipated Upcoming Milestones
FTD-GRN
Initiate dosing for Cohort 2 FTD-GRN patients in 1H 2024 Report full 6-month safety and biomarker data from Cohort 1 patients in 2H 2024 Report 12-month follow-up data from Cohort 1 patients in 1H 2025 Report initial safety and biomarker data from Cohort 2 patients in 1H 2025 FTD-C9orf72 and ALS
Obtain regulatory feedback on the pathway to treating FTD-C9orf72 and ALS patients with PBFT02 in 2H 2024 These strategic priorities and clinical milestones underscore Passage Bio's dedication to advancing cutting-edge, one-time genetic medicines and protecting patients and families against loss in neurodegenerative conditions.
Conference Call Details
Passage Bio will host a conference call and webcast today at 8:30 a.m. ET. To register for the event, please use the following link investors.passagebio.com
About upliFT-D (NCT04747431)
upliFT-D is a Phase 1/2 global, multi-center, open-label, dose-escalation clinical trial of PBFT02 administered by single injection into the cisterna magna in patients aged 35 to 75 years with FTD-GRN.
The upliFT-D clinical trial will investigate two dose levels of PBFT02. The clinical trial will sequentially enroll two cohorts, with an optional third dose level cohort expected to be enrolled based on the results of the first two cohorts. Enrollment is currently ongoing. The primary endpoint of the clinical trial is to evaluate the safety and tolerability of PBFT02. Secondary endpoints include disease biomarkers and clinical outcome measures. upliFT-D is a two-year clinical trial with a three-year safety extension. Passage Bio is pursuing several initiatives to support clinical trial recruitment and enrollment, including a collaborative partnership with InformedDNA to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with FTD. More information about upliFT-D can be found here.
About PBFT02
PBFT02 utilizes an AAV1 viral vector to deliver, through ICM administration, a functional GRN gene to patients with mutations in the gene that encodes for progranulin (PGRN). This vector and delivery approach aims to provide higher-than-normal levels of the PGRN protein to the CNS to overcome the progranulin deficiency in GRN gene mutation carriers.
PBFT02 is supported by extensive preclinical studies conducted by Passage Bio’s collaborator, the University of Pennsylvania’s Gene Therapy Program. The studies showed compelling evidence indicating broad transduction across the brain, including high transduction of ependymal cells, and demonstrated robust increases in cerebrospinal fluid (CSF) PGRN concentrations.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com .
Forward-Looking Statements
For further information, please contact:
Investors:mnafus@passagebio.com
Media:MikeBeyer@sambrown.com
What is the purpose of the upliFT-D clinical trial by Passage Bio, Inc. (PASG)?
The upliFT-D clinical trial evaluates PBFT02, an adeno-associated virus (AAV)-delivery gene therapy, as a treatment for patients with frontotemporal dementia (FTD) with granulin (GRN) mutations.
What are the strategic priorities announced by Passage Bio, Inc. (PASG)?
Passage Bio, Inc. (PASG) is focused on continuing the clinical development of PBFT02 to treat FTD-GRN, pursuing PBFT02 in additional adult neurodegenerative diseases, prioritizing Huntington’s disease preclinical program, and exploring potential partnership opportunities for clinical-stage pediatric programs.
What are the anticipated upcoming milestones for Passage Bio, Inc. (PASG)?
Anticipated upcoming milestones include initiating dosing for Cohort 2 FTD-GRN patients, reporting full 6-month safety and biomarker data from Cohort 1 patients, reporting 12-month follow-up data from Cohort 1 patients, and reporting initial safety and biomarker data from Cohort 2 patients.
What is the conference call and webcast event hosted by Passage Bio, Inc. (PASG)?
Passage Bio, Inc. (PASG) will host a conference call and webcast to review interim FTD data at 8:30 a.m. ET. The event will be available on the Investors & News section of Passage Bio’s website.
